Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Journal of Cancer Immunology & Therapy (2024) Volume 7, Issue 1

Illuminating the Role of Photosensitizers in Photodynamic Therapy.

Leonard Ghate *

Department of Food Science and Technology, National University of Singapore, Singapore

*Corresponding Author:
Leonard Ghate
Department of Food Science and Technology, National University of Singapore, Singapore
E-mail: leonard@nus.edu.sg

Received: 02-Feb -2024, Manuscript No. AAJCIT-24-129812; Editor assigned: 03-Feb-2024, PreQC No. AAJCIT-24-129812 (PQ); Reviewed:17-Feb-2024, QC No. AAJCIT-24-129812; Revised:22-Feb-2024, Manuscript No. AAJCIT-24-129812 (R); Published:29-Feb-2024, DOI:10.35841/aara-7.1.188

Citation: Ghate L., Illuminating the role of photosensitizers in photodynamic therapy. J Cancer Immunol Ther. 2024;7(1):188

Visit for more related articles at Journal of Cancer Immunology & Therapy

Introduction

In recent years, PDT has garnered significant attention for its effectiveness, minimal invasiveness, and potential to treat a wide range of medical conditions. Central to the success of PDT are the photosensitizers themselves, which play a pivotal role in harnessing light energy to induce therapeutic responses. This article delves into the multifaceted role of photosensitizers in photodynamic therapy, exploring their mechanisms of action, types, and applications in clinical practice [1].

At the core of photodynamic therapy lies the concept of photosensitization – the process by which photosensitizers become activated upon exposure to specific wavelengths of light. Photosensitizers are typically organic or inorganic compounds that possess the ability to absorb photons and undergo photochemical reactions, generating reactive oxygen species (ROS) such as singlet oxygen and free radicals. These ROS, in turn, inflict oxidative damage on target cells, leading to apoptosis, necrosis, or immune-mediated cell death [2].

One of the key characteristics of photosensitizers is their ability to accumulate selectively in target tissues, a phenomenon known as preferential localization. This selective uptake can be attributed to various factors, including enhanced permeability and retention (EPR) effect, specific cellular uptake mechanisms, and tumor microenvironmental factors. By exploiting the preferential accumulation of photosensitizers in diseased tissues, PDT offers a localized and targeted approach to treatment, minimizing damage to healthy surrounding tissues [3].

Porphyrin-based photosensitizers, such as Photofrin® and porfimer sodium, were among the first clinically approved agents for PDT and have demonstrated efficacy in treating various cancers, including esophageal, lung, and bladder cancers. Additionally, second-generation photosensitizers, such as 5-aminolevulinic acid (ALA) and its derivatives, offer improved selectivity and pharmacokinetic properties, expanding the utility of PDT in dermatology and oncology [4].

In recent years, the field of nanomedicine has witnessed the emergence of nanotechnology-based photosensitizers, including liposomes, polymeric nanoparticles, and carbon nanomaterials. These nanoscale platforms offer several advantages, including enhanced stability, prolonged circulation time, and tunable physicochemical properties. Furthermore, nanocarriers can be engineered to encapsulate photosensitizers and facilitate their targeted delivery to specific tissues or cellular compartments, thereby enhancing therapeutic efficacy and reducing off-target effects [5].

The choice of photosensitizer depends on several factors, including the type and location of the target tissue, the depth of light penetration required, and the desired therapeutic outcome. For superficial lesions, such as actinic keratoses and skin cancers, topical photosensitizers administered via cream or gel formulations are often preferred due to their ease of application and localized effects. Conversely, for deeper-seated tumors or internal malignancies, systemic administration of photosensitizers via intravenous injection allows for deeper tissue penetration and broader therapeutic coverage [6].

Beyond oncology, photodynamic therapy has found applications in various medical disciplines, including dermatology, ophthalmology, and infectious diseases. In dermatology, PDT is used to treat precancerous skin lesions, acne, and photodamaged skin, offering a non-invasive alternative to conventional treatments. Additionally, PDT has shown promise in the treatment of infectious diseases, such as microbial keratitis and multidrug-resistant bacterial infections, owing to its broad-spectrum antimicrobial activity [7].

Despite its numerous advantages, photodynamic therapy faces certain limitations and challenges, including limited tissue penetration of light, photosensitivity reactions, and the need for specialized equipment and trained personnel. Moreover, the development of resistance to PDT and the optimization of treatment parameters remain areas of active research and clinical investigation. Nonetheless, ongoing advancements in photosensitizer design, light delivery systems, and treatment protocols hold promise for overcoming these hurdles and expanding the therapeutic utility of PDT in the years to come [8].

Photosensitizers used in photodynamic therapy encompass a diverse array of compounds, ranging from naturally occurring porphyrins and chlorins to synthetic derivatives and nanoparticles. In ophthalmology, PDT has been employed for the management of age-related macular degeneration (AMD) and certain ocular tumors, preserving vision and preventing disease progression [9].

Photodynamic therapy (PDT) stands as a promising modality in the realm of cancer treatment and dermatology. It involves the use of light-sensitive compounds called photosensitizers to selectively destroy cancer cells or target abnormal tissue while sparing healthy surrounding tissue [10].

conclusion

In conclusion, the intersection of advocacy and research serves as a powerful force for change in the field of breast cancer care. Together, advocates and researchers are driving progress towards improved prevention, early detection, personalized treatment, and survivorship support. By harnessing the collective efforts of stakeholders worldwide, we can strive towards a future where every individual impacted by breast cancer receives the care and support they deserve, ultimately leading to a world without breast cancer.

References

  1. Zhang S, Chopin M, Nutt SL. Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy. Trends Immunol. 2021;42(12):1113-27.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kuryk L, Bertinato L, Staniszewska M, et al. From conventional therapies to immunotherapy: melanoma treatment in review. Cancer. 2020;12(10):3057.

    3. Indexed at, Google Scholar, Cross Ref

  3. Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21(114):125-33.

    4. Indexed at, Google Scholar

  4. Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286-301.

    5. Indexed at, Google Scholar, Cross Ref

  5. Li K, Zhang Z, Mei Y, et al. Targeting the innate immune system with nanoparticles for cancer immunotherapy. J Mater Chem B. 2022;10(11):1709-33.

    6. Indexed at, Google Scholar, Cross Ref

  6. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non–small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer. 2010;11(4):228-37.

    7. Indexed at, Google Scholar, Cross Ref

  7. Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7-24.

    8. Indexed at, Google Scholar, Cross Ref

  8. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol. 2000;34(1):1-25.

    9. Indexed at, Google Scholar, Cross Ref

  9. Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206.

    10. Indexed at, Google Scholar, Cross Ref

  10. Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551-66.

    11. Indexed at, Google Scholar, Cross Ref

Get the App